MedTrace Logo

Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients

NCT05346783 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2022-04-26

No results posted yet for this study

Summary

This is a prospective randomized study compared with active control and placebo arms.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

TJO-083

Diquafosol ophthalmic sodium solution, 1 drop 3 times a day

OTHER

Placebo (vehicle)

1 drop 6 times a day

DRUG

Diquafosol ophthalmic sodium solution 3%

Diquafosol ophthalmic sodium solution, 1 drop 6 times a day

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hyung Keun Lee, MD · Gangnam Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-14
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346783 on ClinicalTrials.gov